{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T01:15:21Z","timestamp":1755998121080,"version":"3.38.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.vph.2024.107444","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T17:22:15Z","timestamp":1733246535000},"page":"107444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Prevalence of antiphospholipid antibodies in COVID-19 patients: A meta-analysis"],"prefix":"10.1016","volume":"158","author":[{"given":"Er","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaonan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Runlan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenhong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2024.107444_bb0005","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.vph.2024.107444_bb0010","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/bjh.16727","article-title":"Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action","volume":"189","author":"Kollias","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.vph.2024.107444_bb0015","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s11239-020-02318-x","article-title":"COVID-19 associated coagulopathy in critically ill patients: a hypercoagulable state demonstrated by parameters of haemostasis and clot waveform analysis","volume":"51","author":"Fan","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.vph.2024.107444_bb0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.thromres.2020.04.024","article-title":"Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy","volume":"191","author":"Lodigiani","year":"2020","journal-title":"Thromb. Res."},{"key":"10.1016\/j.vph.2024.107444_bb0025","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/jmv.25770","article-title":"Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19","volume":"92","author":"Gao","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.vph.2024.107444_bb0030","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood.2020006520","article-title":"COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection","volume":"136","author":"Al-Samkari","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.vph.2024.107444_bb0035","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1097\/CCM.0000000000004458","article-title":"Coagulopathy of coronavirus disease 2019","volume":"48","author":"Iba","year":"2020","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.vph.2024.107444_bb0040","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1111\/jth.14888","article-title":"Incidence of venous thromboembolism in hospitalized patients with COVID-19","volume":"18","author":"Middeldorp","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.vph.2024.107444_bb0045","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41584-020-0474-5","article-title":"Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications","volume":"16","author":"Merrill","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.vph.2024.107444_bb0050","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/joim.13123","article-title":"Viral infections and their relationship with catastrophic antiphospholipid syndrome: a possible pathogenic mechanism of severe COVID-19 thrombotic complications","volume":"288","author":"Mendoza-Pinto","year":"2020","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.vph.2024.107444_bb0055","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jaut.2014.01.006","article-title":"Diagnosis and classification of the antiphospholipid syndrome","volume":"48-49","author":"Gomez-Puerta","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.vph.2024.107444_bb0060","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/acr.24468","article-title":"Characteristics of patients with antiphospholipid antibody positivity in the APS ACTION international clinical database and repository","volume":"74","author":"Sevim","year":"2022","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.vph.2024.107444_bb0065","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.3389\/fimmu.2019.01609","article-title":"Environmental triggers of autoreactive responses: induction of antiphospholipid antibody formation","volume":"10","author":"Martirosyan","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.vph.2024.107444_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.33349","article-title":"International consensus guidelines on anticardiolipin and anti-beta2-glycoprotein I testing: report from the 13th international congress on antiphospholipid antibodies","volume":"64","author":"Lakos","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.vph.2024.107444_bb0075","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13075-016-1018-x","article-title":"Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers","volume":"18","author":"Roggenbuck","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.vph.2024.107444_bb0080","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nrrheum.2017.124","article-title":"Diagnosing antiphospholipid syndrome: \u2018extra-criteria\u2019 manifestations and technical advances","volume":"13","author":"Sciascia","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.vph.2024.107444_bb0085","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1177\/0961203317731532","article-title":"Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis","volume":"27","author":"Abdel-Wahab","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.vph.2024.107444_bb0090","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/ijlh.13805","article-title":"Profile of antiphospholipid antibodies in HIV-infected and HIV-uninfected women with a history of thrombosis","volume":"44","author":"Schapkaitz","year":"2022","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.vph.2024.107444_bb0095","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1177\/0961203316640912","article-title":"Systematic review of case reports of antiphospholipid syndrome following infection","volume":"25","author":"Abdel-Wahab","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.vph.2024.107444_bb0100","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11926-018-0773-x","article-title":"Role of infectious diseases in the antiphospholipid syndrome (including its catastrophic variant)","volume":"20","author":"Mendoza-Pinto","year":"2018","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.vph.2024.107444_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1038712","article-title":"Comprehensive assessment of SARS-CoV-2 antibodies against various antigenic epitopes after naive COVID-19 infection and vaccination (BNT162b2 or ChAdOx1 nCoV-19)","volume":"13","author":"Lee","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.vph.2024.107444_bb0110","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jcrc.2020.05.017","article-title":"Clinically significant anticardiolipin antibodies associated with COVID-19","volume":"59","author":"Hossri","year":"2020","journal-title":"J. Crit. Care"},{"key":"10.1016\/j.vph.2024.107444_bb0115","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/joim.13126","article-title":"High frequency of antiphospholipid antibodies in critically ill COVID-19 patients: a link with hypercoagulability?","volume":"289","author":"Pineton de Chambrun","year":"2021","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.vph.2024.107444_bb0120","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2007575","article-title":"Coagulopathy and antiphospholipid antibodies in patients with Covid-19","volume":"382","author":"Zhang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2024.107444_bb0125","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/acr2.11245","article-title":"Beta-2-glycoprotein-I deficiency could precipitate an antiphospholipid syndrome-like Prothrombotic situation in patients with coronavirus disease 2019","volume":"3","author":"Serrano","year":"2021","journal-title":"ACR Open Rheumatol."},{"key":"10.1016\/j.vph.2024.107444_bb0130","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001580","article-title":"Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review","volume":"7","author":"Taha","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.vph.2024.107444_bb0135","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-218100","article-title":"Presence of antiphospholipid antibodies in COVID-19: a case series study","volume":"80","author":"Amezcua-Guerra","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.vph.2024.107444_bb0140","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1007\/s10067-021-05580-3","article-title":"Anti-phospholipids antibodies and immune complexes in COVID-19 patients: a putative role in disease course for anti-annexin-V antibodies","volume":"40","author":"Cristiano","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.vph.2024.107444_bb0145","first-page":"9","article-title":"Anti-phospholipid antibodies and COVID-19 thrombosis: a co-star, not a supporting actor","author":"Gil-Etayo","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.vph.2024.107444_bb0150","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.24004","article-title":"Assessment of antiphospholipid antibodies and calprotectin as biomarkers for discriminating mild from severe COVID-19","volume":"35","author":"Lee","year":"2021","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.vph.2024.107444_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010118","article-title":"Anti-prothrombin autoantibodies enriched after infection with SARS-CoV-2 and influenced by strength of antibody response against SARS-CoV-2 proteins","volume":"17","author":"Emmenegger","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.vph.2024.107444_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1129201","article-title":"Antiphospholipid antibodies in patients with stroke during COVID-19: a role in the signaling pathway leading to platelet activation","volume":"14","author":"Capozzi","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.vph.2024.107444_bb0165","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.amjms.2022.10.012","article-title":"Anticardiolipin and anti-beta-2 glycoprotein I antibodies in patients with moderate or severe COVID-19","volume":"365","author":"Garcia-Arellano","year":"2023","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.vph.2024.107444_bb0170","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.thromres.2023.01.016","article-title":"Decreased protein C activity, lower ADAMTS13 antigen and free protein S levels accompanied by unchanged thrombin generation potential in hospitalized COVID-19 patients","volume":"223","author":"Wojcik","year":"2023","journal-title":"Thromb. Res."},{"key":"10.1016\/j.vph.2024.107444_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/v16071071","article-title":"IgA anti-beta2-glycoprotein I antibodies as markers of thrombosis and severity in COVID-19 patients","volume":"16","author":"Mellor-Pita","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.vph.2024.107444_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108426","article-title":"On the molecular determinants of the SARS-CoV-2 attack","volume":"215","author":"Kanduc","year":"2020","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.vph.2024.107444_bb0185","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41392-020-00334-0","article-title":"SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.vph.2024.107444_bb0190","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1165\/rcmb.2016-0011PS","article-title":"Surfactant lipids at the host-environment Interface. Metabolic sensors, suppressors, and effectors of inflammatory lung disease","volume":"54","author":"Fessler","year":"2016","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.vph.2024.107444_bb0195","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/art.41425","article-title":"Antiphospholipid antibodies in critically ill patients with COVID-19","volume":"72","author":"Xiao","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.vph.2024.107444_bb0200","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1111\/jth.14994","article-title":"Antiphospholipid antibodies in patients with COVID-19: a relevant observation?","volume":"18","author":"Devreese","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.vph.2024.107444_bb0205","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.thromres.2020.07.016","article-title":"Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?","volume":"195","author":"Siguret","year":"2020","journal-title":"Thromb. Res."},{"key":"10.1016\/j.vph.2024.107444_bb0210","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11926-013-0343-1","article-title":"Clinical significance of IgA anti-cardiolipin and IgA anti-beta2glycoprotein I antibodies","volume":"15","author":"Andreoli","year":"2013","journal-title":"Curr. Rheumatol. Rep."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189124001708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189124001708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T10:13:42Z","timestamp":1741256022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189124001708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":42,"alternative-id":["S1537189124001708"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2024.107444","relation":{},"ISSN":["1537-1891"],"issn-type":[{"type":"print","value":"1537-1891"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of antiphospholipid antibodies in COVID-19 patients: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2024.107444","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107444"}}